These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 32250730)

  • 1. Sporadic Angiomyolipomas Growth Kinetics While on Everolimus: Results of a Phase II Trial.
    Geynisman DM; Kadow BT; Shuch BM; Boorjian SA; Matin SF; Rampersaud E; Milestone BN; Plimack ER; Zibelman MR; Kutikov A; Smaldone MC; Chen DY; Viterbo R; Joshi S; Greenberg RE; Malizzia L; McGowan T; Ross EA; Uzzo RG
    J Urol; 2020 Sep; 204(3):531-537. PubMed ID: 32250730
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessing the outcomes of everolimus on renal angiomyolipoma associated with tuberous sclerosis complex in China: a two years trial.
    Cai Y; Guo H; Wang W; Li H; Sun H; Shi B; Zhang Y
    Orphanet J Rare Dis; 2018 Mar; 13(1):43. PubMed ID: 29587809
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Angiomyolipoma rebound tumor growth after discontinuation of everolimus in patients with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis.
    Bissler JJ; Nonomura N; Budde K; Zonnenberg BA; Fischereder M; Voi M; Louveau AL; Herbst F; Bebin EM; Curatolo P; Zonta A; Belousova E
    PLoS One; 2018; 13(9):e0201005. PubMed ID: 30192751
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Everolimus for renal angiomyolipoma in patients with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis: extension of a randomized controlled trial.
    Bissler JJ; Kingswood JC; Radzikowska E; Zonnenberg BA; Frost M; Belousova E; Sauter M; Nonomura N; Brakemeier S; de Vries PJ; Berkowitz N; Miao S; Segal S; Peyrard S; Budde K
    Nephrol Dial Transplant; 2016 Jan; 31(1):111-9. PubMed ID: 26156073
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Everolimus long-term use in patients with tuberous sclerosis complex: Four-year update of the EXIST-2 study.
    Bissler JJ; Kingswood JC; Radzikowska E; Zonnenberg BA; Belousova E; Frost MD; Sauter M; Brakemeier S; de Vries PJ; Berkowitz N; Voi M; Peyrard S; Budde K
    PLoS One; 2017; 12(8):e0180939. PubMed ID: 28792952
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial.
    Bissler JJ; Kingswood JC; Radzikowska E; Zonnenberg BA; Frost M; Belousova E; Sauter M; Nonomura N; Brakemeier S; de Vries PJ; Whittemore VH; Chen D; Sahmoud T; Shah G; Lincy J; Lebwohl D; Budde K
    Lancet; 2013 Mar; 381(9869):817-24. PubMed ID: 23312829
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CT characteristics predict the response to everolimus or sirolimus of renal angiomyolipomas in patients with tuberous sclerosis complex.
    Wang W; Guo H; Shi B; Sun H; Li H; Zhang Y; Cai Y
    Int Urol Nephrol; 2019 Apr; 51(4):671-676. PubMed ID: 30756282
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of everolimus on tuberous sclerosis complex-associated renal angiomyolipoma: A preliminary report.
    Tsai JD; Wei CC; Yang SH; Fan HC; Hsu CC; Tung MC; Tsai ML; Sheu JN
    Nephrology (Carlton); 2017 Dec; 22(12):1017-1022. PubMed ID: 27565896
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intermittent everolimus administration for renal angiomyolipoma associated with tuberous sclerosis complex.
    Hatano T; Inaba H; Endo K; Egawa S
    Int J Urol; 2017 Nov; 24(11):780-785. PubMed ID: 28905429
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of everolimus treatment for regrown renal angiomyolipoma associated with tuberous sclerosis complex after transcatheter arterial embolization.
    Hatano T; Matsu-Ura T; Mori KI; Inaba H; Endo K; Tamari M; Egawa S
    Int J Clin Oncol; 2018 Dec; 23(6):1134-1139. PubMed ID: 30069798
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of everolimus on renal angiomyolipoma in pediatric patients with tuberous sclerosis being treated for subependymal giant cell astrocytoma.
    Bissler JJ; Franz DN; Frost MD; Belousova E; Bebin EM; Sparagana S; Berkowitz N; Ridolfi A; Kingswood JC
    Pediatr Nephrol; 2018 Jan; 33(1):101-109. PubMed ID: 28993887
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcomes of everolimus treatment for renal angiomyolipoma associated with tuberous sclerosis complex: A single institution experience in Japan.
    Hatano T; Chikaraishi K; Inaba H; Endo K; Egawa S
    Int J Urol; 2016 Oct; 23(10):833-838. PubMed ID: 27480662
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of everolimus on skin lesions in patients treated for subependymal giant cell astrocytoma and renal angiomyolipoma: final 4-year results from the randomized EXIST-1 and EXIST-2 studies.
    Franz DN; Budde K; Kingswood JC; Belousova E; Sparagana S; de Vries PJ; Berkowitz N; Ridolfi A; Bissler JJ
    J Eur Acad Dermatol Venereol; 2018 Oct; 32(10):1796-1803. PubMed ID: 29569806
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of everolimus on renal angiomyolipoma in patients with tuberous sclerosis complex being treated for subependymal giant cell astrocytoma: subgroup results from the randomized, placebo-controlled, Phase 3 trial EXIST-1.
    Kingswood JC; Jozwiak S; Belousova ED; Frost MD; Kuperman RA; Bebin EM; Korf BR; Flamini JR; Kohrman MH; Sparagana SP; Wu JY; Brechenmacher T; Stein K; Berkowitz N; Bissler JJ; Franz DN
    Nephrol Dial Transplant; 2014 Jun; 29(6):1203-10. PubMed ID: 24729041
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis.
    Bissler JJ; McCormack FX; Young LR; Elwing JM; Chuck G; Leonard JM; Schmithorst VJ; Laor T; Brody AS; Bean J; Salisbury S; Franz DN
    N Engl J Med; 2008 Jan; 358(2):140-51. PubMed ID: 18184959
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of everolimus treatment for renal angiomyolipoma associated with tuberous sclerosis complex: an evaluation based on tumor density.
    Hatano T; Atsuta M; Inaba H; Endo K; Egawa S
    Int J Clin Oncol; 2018 Jun; 23(3):547-552. PubMed ID: 29256023
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics and pharmacodynamics of everolimus in patients with renal angiomyolipoma and tuberous sclerosis complex or lymphangioleiomyomatosis.
    Budde K; Zonnenberg BA; Frost M; Cheung W; Urva S; Brechenmacher T; Stein K; Chen D; Kingswood JC; Bissler JJ
    Br J Clin Pharmacol; 2016 May; 81(5):958-70. PubMed ID: 26580489
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Everolimus in pregnancy: Case report and literature review.
    Yamamura M; Kojima T; Koyama M; Sazawa A; Yamada T; Minakami H
    J Obstet Gynaecol Res; 2017 Aug; 43(8):1350-1352. PubMed ID: 28557245
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mutational analysis of renal angiomyolipoma associated with tuberous sclerosis complex and the outcome of short-term everolimus therapy.
    Ni J; Yan F; Qin W; Yu L; Zhang G; Liu F; Yang X; Yang B; Hao C; Wang T; Liu P; Yuan J; Wu G
    Sci Rep; 2019 Oct; 9(1):14337. PubMed ID: 31586081
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sequential everolimus for angiomyolipoma associated with tuberous sclerosis complex: a prospective cohort study.
    Gu L; Peng C; Zhang F; Fang C; Guo G
    Orphanet J Rare Dis; 2021 Jun; 16(1):277. PubMed ID: 34127034
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.